Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo filed this Form 8-K on October 3, 2023, under Item 8.01, to disclose the Chapter 11 bankruptcy filing of its wholly owned subsidiary, Zymergen Inc., and certain Zymergen subsidiaries. Neither Ginkgo nor its other subsidiaries filed for bankruptcy. Ginkgo stated that it and its other subsidiaries would continue operating as usual.
Financial position and transaction terms
- Ginkgo reported $1.1 billion of cash and cash equivalents at the end of the second quarter of 2023.
- The filing states that Ginkgo remained well capitalized to execute its long-term strategy.
- The filing does not provide current-period revenue, profit, cash-flow, margin, or debt figures.
- Ginkgo entered into an asset purchase agreement to act as the stalking-horse bidder under Section 363 of the Bankruptcy Code for substantially all of Zymergen’s intellectual property assets and certain other relevant assets.
- The bid includes $5 million of cash and the assumption of up to $77 million of potential future liabilities, including a lease already included in Ginkgo’s consolidated financial statements and employee compensation and severance costs.
Material changes versus the prior comparable period
The principal disclosed development is Zymergen’s voluntary Chapter 11 filing on October 3, 2023. Ginkgo said it was aware of Zymergen’s significant contingent liabilities when it acquired Zymergen in October 2022 and that Zymergen had always operated as a distinct legal entity separate from Ginkgo.
Ginkgo also disclosed that it had previously entered into an arms-length, non-exclusive license with Zymergen covering intellectual property, databases, automation, and software capabilities. Ginkgo stated that the bankruptcy process would not affect this license or its rights under it.
Guidance, outlook, risks, contingencies, and unusual items
- The stalking-horse bid remains subject to the bankruptcy process and applicable court and transaction requirements.
- Potential liabilities assumed under the bid may reach $77 million; the filing does not establish the ultimate amount or timing of those liabilities.
- The bankruptcy introduces execution, legal, employee-cost, lease, and asset-transfer risks related to the proposed acquisition.
- Ginkgo characterized the impact on its operations as limited, stating that its other businesses would continue operating as usual.
- No formal revenue, earnings, cash-flow, or margin guidance was provided in this filing.
Key facts investors should verify
- The final court-approved terms and outcome of the Zymergen asset sale process.
- The ultimate amount and timing of liabilities assumed by Ginkgo, including lease, compensation, and severance obligations.
- Whether Ginkgo’s $1.1 billion cash balance and capitalization have changed materially since the end of the second quarter of 2023.
- The continuing enforceability and scope of Ginkgo’s existing non-exclusive Zymergen intellectual-property license.
- Any subsequent disclosures regarding the financial or operational effects of Zymergen’s bankruptcy on Ginkgo.